Across TCGA pan-cancer cohorts, IGLV4-3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGLV4-3 data layer compared with 17 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher IGLV4-3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV4-3 expression acts as an unfavorable survival marker.

DLBC, LUSC, and SKCM are the cancer types where IGLV4-3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
LUSC	DFS	Median	All	0.064	0.791	<.001	6	view →
SKCM	OS	Median	II,III,IV	0.478	0.738	.016	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGLV4-3 tumor-vs-normal RNA expression · all IGLV4-3 data types